Search Results for “dealforma” – Page 3 – Endpoints News

SIGN UP

search results for: dealforma

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

3 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

3 years ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

3 years ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

3 years ago

H1 analysis: The high-stakes table in the biotech deals casino is paying out some record-setting winnings

3 years ago

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to ...

3 years ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

3 years ago

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

3 years ago

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to ...

3 years ago

Going gangbusters: The top 20 biotech platform deals by upfront cash

3 years ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

3 years ago

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

3 years ago

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

3 years ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel ...

3 years ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

3 years ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

3 years ago

Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B

3 years ago

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

3 years ago

First page Previous page 1 234 Next page Last page

latest

Most read

Merck wins legal battle over insurance coverage after ransomware attack

Yesterday

What lured Hal Barron away?; Top FDA minds on accelerated approval reforms; ‘Dead wrong’ Aduhelm ad blitz; and ...

3 hours ago

Critics push back on Alzheimer’s Association ad blitz to get Medicare to change its Aduhelm ruling: 'Dead wrong'

22 hours ago

Failing to confirm clinical benefit, Gilead pulls 2 accelerated approval indications for cancer drug

22 hours ago

Yingli Pharma brings small molecule research to the US in new pact with MD Anderson; UCB's psoriatic arthritis drug ...

22 hours ago

see latest stream